Evidence-based recommendations on the NIOX MINO, NIOX VERO and Nobreath devices to measure fractional exhaled nitric oxide concentration in asthma
Evidence-based recommendations on SeHCAT (tauroselcholic [75 selenium] acid) for investigating diarrhoea due to bile acid malabsorption (BAM)
Evidence-based recommendations on the Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M depth of anaesthesia monitors
Evidence-based recommendations on theSonoVue (sulphur hexafluoride microbubbles) contrast agent for contrast-enhanced ultrasound imaging of the liver
Evidence-based recommendations on point-of-care coagulometers (the CoaguChek XS system) to self-monitor blood clotting
Evidence-based recommendations on high-sensitivity troponin tests for the early rule-out of acute myocardial infarction (AMI)
Evidence-based recommendations on integrated multiplex polymerase chain tests for identifying gastrointestinal pathogens in suspected gastroenteritis
Evidence-based recommendations on tests (IOTA ADNEX, Overa, RMI I, ROMA, IOTA Simple Rules) in secondary care to identify people at high risk of ovarian cancer
Evidence-based recommendations on ImmunoCAP ISAC 112 and Microtest for multiplex allergen testing to diagnose allergy and predict the risk of allergic reaction
Evidence-based recommendations on PlGF-based testing to help diagnose suspected pre-eclampsia
Evidence-based recommendations on the MiniMed Paradigm Veo and Vibe and G4 PLATINUM CGM sensor-augmented pump therapy systems for type 1 diabetes
Evidence-based recommendations on the LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay for identifying bloodstream bacteria and fungi
Evidence-based recommendations on new generation computed tomography (CT) scanners for cardiac imaging for suspected or known coronary artery disease
Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy
Evidence-based recommendations on VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions
Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (AVIDA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive..
Evidence-based recommendations on faecal calprotectin diagnostic tests for inflammatory diseases of the bowel
Evidence-based recommendations on the EOS 2D/3D imaging system for radiological examinations
Evidence-based recommendations on multi frequency bioimpedance devices to guide fluid management for people with chronic kidney disease having dialysis
Evidence-based recommendations on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer
Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis
Evidence-based recommendations on biomarker tests (Actim Partus, PartoSure, Rapid fFN 10Q Cassette) to diagnose preterm labour in women with intact membranes
Evidence-based recommendations on DYSIS colposcope with DYSISmap and ZedScan I for assessing suspected cervical abnormalities in people having colposcopy
Evidence-based recommendations on lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care
Evidence-based recommendations on rapid tests for group A streptococcal (strep A) infections in people aged 5 and over with a sore throat
Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast
Evidence-based recommendations on immunohistochemistry/microsatellite instability testing to guide tests for Lynch syndrome in people with colon cancer
Evidence-based recommendations on therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in breast cancer
Evidence-based recommendations on EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on viscoelastometric point-of-care testing (ROTEM, TEG and Sonoclot systems) to detect, manage and monitor haemostasis
Evidence-based recommendations on the My5-FU assay for guiding dose adjustment for fluorouracil chemotherapy
In development [GID-DG10034] Expected publication date: 30 September 2020
In development [GID-DG10035] Expected publication date: 26 August 2020
In development [GID-DG10028] Expected publication date: 22 April 2020
In development [GID-DG10023] Expected publication date: TBC
In development [GID-DG10029] Expected publication date: 08 July 2020
In development [GID-DG10033] Expected publication date: 29 July 2020
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.
This guideline covers how healthcare services for people with skin cancers should be organised. It aims to improve diagnosis and care by recommending which healthcare professionals should be involved and at which stage.
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
This guideline covers how healthcare services for adults with head and neck cancers should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
This guideline covers how healthcare services for people with brain tumours and other central nervous system tumours should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
This guideline covers how healthcare services for children and young people with cancer should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
This guideline covers diagnosing and managing constipation in children and young people up to 18. It provides strategies to support the early identification and timely, effective treatment of constipation which will help improve outcomes for patients. It does not cover constipation caused by a specific condition.
This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.
This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.
This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.